Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 20Lung Neoplasms 6Small Cell Lung Carcinoma 4Ovarian Neoplasms 4Neoplasms 4Colorectal Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Multiple Myeloma 3Lymphoma, Large B-Cell, Diffuse 3Breast Neoplasms 3Vulvar Neoplasms 2Vaginal Neoplasms 2Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Lymphoma, Non-Hodgkin 2Head and Neck Neoplasms 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Carcinoma, Hepatocellular 2Urothelial Cancer 1Urinary Bladder Diseases 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Thrombocytosis 1Testicular Neoplasms 1

Interventions

tislelizumab 3Paclitaxel 3Nivolumab 3pembrolizumab 2atezolizumab 2Docetaxel 2ulocuplumab 1tazemetostat 1tazarotene 1seviteronel 1rucaparib 1romiplostim 1phosphorylethanolamine 1pertuzumab 1neratinib 1magrolimab 1fluzoparib 1fludarabine 1epacadostat 1durvalumab 1camrelizumab 1Trastuzumab 1Sunitinib 1Poly(ADP-ribose) Polymerase Inhibitors 1LY2510924 1EC145 1Cyclophosphamide 1CH5183284 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Solid Tumor × durvalumab × Clear all
NCT02737072 2019-08-12

A Study of LY2510924 and Durvalumab in Participants With Solid Tumors

Eli Lilly and Company

Phase 1 Terminated
9 enrolled 13 charts
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡